jromero@crf.org
Cardiovascular Research Foundation
Results of the TRYTON trial presented at TCT 2013 Clinical trial finds that a strategy of using of a bare metal stent in the side branch for true bifurcation coronary lesions is safe, but does not meet non-inferiority endpoint compared to provisional stenting SAN FRANCISCO, CA – October 30, 2013 – A clinical trial designed to measure the effectiveness of using a dedicated side branch-covering bare metal stent in true bifurcation coronary lesions found that that the strategy was safe, but the results did not establish non-inferiority compared to the currently accepted strategy of using a single stent with provisional use of a second side branch stent when indicated.
The findings of the TRYTON trial were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Coronary bifurcation lesions are caused from a build-up of plaque in the heart at a location where one artery branches from another. Currently, a provisional side-branch stent strategy is the recommended practice in patients with coronary bifurcation lesions. (In provisional stenting strategy, stenting of the side branch is performed only when absolutely necessary.) However, in true bifurcation lesions (disease affecting the origin of both branches), this approach can lead to suboptimal results and even closure of the non-stented branch. The TRYTON trial compared a new specially-designed bare metal bifurcation stent to standard practice. The Tryton stent is placed in the proximal main vessel extending into the side branch. A standard drug-eluting stent (DES) is then placed in the main vessel through the proximal portion of the bifurcation stent into the distal main vessel.
The multicenter international study randomized 704 patients with true coronary bifurcation lesions to receive the new bifurcation stent (355 patients) or provisional stenting (349 patients). The primary endpoint was target vessel failure (TVF), a composite of cardiac death, target vessel myocardial infarction, or target vessel revascularization at nine months.
At nine months, TVF was 12.8 percent in the provisional stenting group, and 17.4 percent in the Tryton stent group.
However, the strategy met the secondary superiority endpoint, improving the percent diameter stenosis of the side branch at nine months. In the provisional group, the percent diameter stenosis was 38.6 and in the bifurcation stent group, the percent diameter stenosis was 31.6. In a post-hoc analysis, the Tryton stent demonstrated improved angiographic outcomes with the bifurcation stent in larger side branches (> 2.25 mm side branches = 39 percent of enrolled patients). Interestingly, the study demonstrated a striking disparity between binary restenosis and clinically-driven TVR for both arms, indicating that side branch angiographic restenosis is uncommonly expressed clinically.
"The two-stent strategy in true bifurcations compared with the provisional strategy did not meet the non-inferiority clinical endpoint (TVF), largely due to a relatively higher frequency of peri-procedural CK-MB elevations," said lead investigator Martin Leon, MD. Dr. Leon is Professor of Medicine at Columbia University College of Physicians and Surgeons and Director of the Center for Interventional Vascular Therapy (CIVT) at NewYork-Presbyterian Hospital/ Columbia University Medical Center. He is also Founder and Chairman Emeritus of CRF.
"However, both strategies were safe resulting in rare clinically significant MIs and stent thrombosis. Both also had low nine-month clinically-driven TVR, with 3.6 percent occurring in the provisional group and 4.7 percent in the bifurcation stent group."
###
The TRYTON trial was funded by Tryton Medical, Inc. Dr. Leon reported research support from Abbott, Boston Scientific, and Medtronic.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.
END